IGF-1LR3
IGF-1LR3 is supplied as a long-acting IGF-1 receptor analog for cell-growth and receptor-signaling pathway research, engineered to reduce binding to IGF-binding proteins so laboratories can isolate IGF-1 receptor activity in culture models. Supplied strictly for laboratory and educational research. Not for human or veterinary use.
Vial amount
Purchase option
Checkout includes a research-use attestation. Materials are supplied only for laboratory and educational research.
IGF-1LR3 in research
IGF-1LR3 is supplied as a long-acting IGF-1 receptor analog for cell-growth and receptor-signaling pathway research, engineered to reduce binding to IGF-binding proteins so laboratories can isolate IGF-1 receptor activity in culture models.
General RUO catalog item for documented laboratory workflows.
Bench context
Supplied as a research-grade reference material for documented laboratory and educational research workflows.
Available amounts
Select from the stocked vial amounts for IGF-1LR3 before adding the material to cart.
Claims discipline
No protocol instructions, no dosing, no medical advice, and no therapeutic or human-use promises.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, not for diagnostic or therapeutic use, not a drug or supplement.
No supplier listing text is on file yet for this item.
The full research picture, clearly labeled
BioRegen reports the entire research landscape for this compound across four clearly separated tiers, strongest evidence first. Lower tiers, including community and anecdotal reports, are labeled as such and are not BioRegen claims.
There are no published human clinical trials of IGF-1 LR3 itself, and it holds no human therapeutic approval in any indication. The native recombinant human IGF-1 molecule (mecasermin, marketed as Increlex) is studied and approved in humans only for severe primary IGF-1 deficiency in children, but that approval applies to the unmodified hormone and not to the LR3 analog, which is a distinct laboratory construct. Reviewers should treat the human-effect evidence base for IGF-1 LR3 specifically as effectively absent.
In research literature, IGF-1 LR3 is described as a long-acting analog of insulin-like growth factor 1, engineered with an Arg3 substitution and an N-terminal extension that reduce its binding to IGF binding proteins and thereby prolong its activity relative to native IGF-1. Investigators use it predominantly as a cell-culture supplement and reference reagent to study IGF-1 receptor signaling, cell proliferation, and growth-factor pathways in vitro. Animal and mechanistic work on IGF-1 biology more broadly is extensive, but findings on the native hormone should not be read as data on this specific analog.
Within biohacker communities, bodybuilding forums, and some mainstream fitness media, IGF-1 analogs are discussed in connection with muscle growth and recovery, and IGF-1 LR3 appears by name in that conversation. Such discussion typically describes self-reported individual experiences rather than measured outcomes, and it frequently omits the safety, purity, and dosing uncertainties that surround unapproved compounds. These accounts are unverified anecdotal commentary, not controlled data, and not a BioRegen claim.
IGF-1 LR3 has no human therapeutic approval from the FDA or comparable regulators, and no IGF-1 product is approved for athletic, anti-aging, or general adult use. As a growth factor, IGF-1 and its analogs fall under category S2 of the World Anti-Doping Agency (WADA) Prohibited List and are banned in sport at all times, both in and out of competition. BioRegen supplies it strictly for laboratory and educational research, not for human use.
Tiers are evidence categories, not endorsements. Clinical and preclinical entries summarize third-party published research. Community and anecdotal entries are unverified reports discussed by others, not findings and not BioRegen claims. Nothing here is medical advice, and no compound is approved for human or veterinary use except where explicitly stated under Regulatory status.
What the published research says about IGF-1LR3
This section reports on published research referenced in BioRegen's own research library. It is not a claim by BioRegen that the compound provides any benefit, and nothing here is medical advice.
- von der Thüsen JH, et al. IGF-1 has plaque-stabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype. Am J Pathol. 2011. https://doi.org/10.1016/j.ajpath.2010.10.007
- Xi G, et al. Effect of recombinant porcine IGFBP-3 on IGF-I and long-R3-IGF-I-stimulated proliferation and differentiation of L6 myogenic cells. J Cell Physiol. 2004. https://doi.org/10.1002/jcp.20068